RTP Mobile Logo
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Gastroesophageal Cancers (Webinar Audio Proceedings)
Released June 2022

Featuring perspectives from Dr Kristen Ciombor and Ms Jessica Mitchell. Published June 17, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with gastroesophageal cancers.

    LEARNING OBJECTIVES

    • Educate patients about how HER2 status, PD-L1 combined positive score and other biologic and clinical factors influence personalized therapeutic recommendations for newly diagnosed locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
    • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric, GEJ and esophageal cancer, and review how these strategies fit into current nonresearch treatment algorithms.
    • Discern how available therapeutic agents and regimens can be applied in the care of patients with HER2-negative metastatic gastric, GEJ and esophageal cancer who have experienced disease progression on front-line chemotherapy or chemoimmunotherapy.
    • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal or GEJ cancer who have residual pathologic disease after neoadjuvant chemoradiation therapy, and discuss the clinical applicability of this strategy with appropriate individuals.
    • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric or GEJ cancer, and counsel patients who may be appropriate for these approaches about the risks and expected benefits.
    • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
    • Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    Audio Program: NCPD credit is no longer available for this issue

    Video Program: NCPD credit is no longer available for this issue

    ONCC/ILNA CERTIFICATION INFORMATION
    NCPD credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    Audio Program: This NCPD activity consists of an audio component.
    NCPD credit is no longer available for this issue

    Video Program: This NCPD activity consists of a video component.
    NCPD credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Kristen K Ciombor, MD, MSCI
    Associate Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee

    Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune; Consulting Agreements: Merck, Pfizer Inc, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc.

    Jessica Mitchell, APRN, CNP, MPH
    Assistant Professor of Oncology
    Mayo Clinic College of Medicine and Science
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Lilly.

    Release date: June 2022
    Expiration date: June 2023

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):